Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MOL has added 4.2% this week to close at HUF 5,055, a quiet consolidation that masks a genuine tension: the borrow market is tightening at the same time the insider register is sending conflicting signals, with Q3 results due on November 6.
The lending picture is the most technically interesting development right now. Borrowing costs have nearly doubled over the past month to 0.68%, reaching a level not seen since mid-May. The direction of travel is clear even if the absolute level remains modest. That said, availability is still extremely loose: roughly 6,800% of outstanding short interest remains available to borrow, meaning there are approximately 16.8 million shares sitting unlent in the pool. That rules out any squeeze mechanics. The short score of 25.7 ranks in the 91st percentile of the ORTEX universe, which sounds alarming until you realise the score reflects how benign the short setup is, not how crowded. Short interest itself is negligible; this is a stock where bears are simply not present in meaningful size.
The Street's position is broadly constructive but the data is stale. The consensus sits at buy, with six buy ratings and one outperform among the analysts ORTEX tracks, and the mean price target of HUF 4,961 is actually a fraction below the current price of HUF 5,055. That gap is worth noting: the stock has run past where analysts last had it, and the most recent recorded target change dates to mid-September. On valuation, the stock trades on a trailing PE of 6.9 and an EV/EBITDA of 3.1, the latter down roughly 10% over 30 days as earnings estimates have been revised. The price-to-book ratio is below 1 at 0.88. The dividend score of 81 and an earnings surprise rank of 80 reflect a company that pays reliably and beats estimates, even if forward momentum has softened.
The insider picture has not materially changed from the note published yesterday, but it bears repeating in the context of the Q3 setup. Board director Zsigmond Járai's EUR 13.6 million open-market purchase in late September remains the dominant buy-side data point and the largest single insider trade in the past 90 days. Against it sit a series of executive-level disposals: the E&P EVP sold roughly HUF 316 million of stock in mid-September, the Downstream EVP cleared HUF 161 million two days earlier, and a further board member sold HUF 40 million at end-August. Net insider activity over 90 days is modestly negative in share count terms, though Járai's single purchase is large enough to distort any simple read of the aggregate. The most charitable interpretation is that one director has conviction at current prices; the less charitable one is that executives closer to the operational numbers saw an exit opportunity near the year's highs.
Recent earnings prints offer limited comfort on direction but suggest the stock can hold its gains through results. The August release produced a 1.4% one-day move and a 6.9% five-day gain. The May print went the other way, with a 1.1% drop on the day extending to a 3.9% decline over the following week. Two data points are not a pattern, but they do confirm the stock can move meaningfully in either direction around results.
With borrowing costs drifting higher, analyst targets now sitting below the market price, and a board split between buyers and sellers, the November 6 print becomes the cleaner arbiter: downstream margins and capital allocation guidance will determine whether Járai's late-September conviction buy looks prescient or premature.
See the live data behind this article on ORTEX.
Open MOL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
